Skip to ContentGo to accessibility pageKeyboard shortcuts menu
OpenStax Logo
Organic Chemistry

Chemistry Matters—Statin Drugs

Organic ChemistryChemistry Matters—Statin Drugs

29 • Chemistry Matters

29 • Chemistry Matters

Coronary heart disease—the buildup of cholesterol-containing plaques on the walls of heart arteries—is the leading cause of death for people older than 20 in industrialized countries. It’s estimated that up to one-third of women and one-half of men will develop the disease at some point in their lives.

The onset of coronary heart disease is directly correlated with blood cholesterol levels (see the Chapter 27 Chemistry Matters), and the first step in disease prevention is to lower those levels. It turns out that only about 25% of your blood cholesterol comes from what you eat; the remaining 75%—about 1 gram each day—is biosynthesized in your liver from dietary fats and carbohydrates. Thus, any effective plan for lowering your cholesterol level means limiting the amount that your body makes, which is where a detailed chemical knowledge of cholesterol biosynthesis comes in.

Cutaway diagram of a blood vessel showing a smooth interior, labeled normal artery. Another cutaway diagram in which vessel is partially obstructed with a yellowish substance, labeled narrowing of artery.
Figure 29.18 The buildup of cholesterol deposits inside arteries can cause coronary heart disease, a leading cause of death for adults in industrialized nations.

We saw in Section 27.5 and Section 27.7 that all steroids, including cholesterol, are biosynthesized from the triterpenoid lanosterol, which in turn comes from acetyl CoA through isopentenyl diphosphate. If you knew all the mechanisms for all the chemical steps in cholesterol biosynthesis, you might be able to devise a drug that would block one of those steps, thereby short-circuiting the biosynthetic process and controlling the amount of cholesterol produced.

But we do know those mechanisms! Look back at the pathway for the biosynthesis of isopentenyl diphosphate from acetyl CoA, shown in Figure 27.8. It turns out that the rate-limiting step in the pathway is the reduction of 3-hydroxy-3-methylglutaryl CoA (abbreviated HMG-CoA) to mevalonate, brought about by the enzyme HMG-CoA reductase. If that enzyme could be stopped from functioning, cholesterol biosynthesis would also be stopped.

The biosynthesis of mevalonate from 3-hydroxy-3-methylglutaryl coenzyme A (HMG-coenzyme A) is shown to be  the rate-limiting step in the biosynthesis of cholesterol.

To find a drug that blocks HMG-CoA reductase, chemists did two simultaneous experiments on a large number of potential drug candidates isolated from soil microbes. In one experiment, the drug candidate and mevalonate were added to liver extract; in the second experiment, only the drug candidate was added without mevalonate. If cholesterol was produced only in the presence of added mevalonate but not in the absence of mevalonate, the drug candidate must have blocked the enzyme for mevalonate synthesis.

The drugs that block HMG-CoA reductase, and thus control cholesterol synthesis in the body, are called statins. In just the 10-year period following their introduction in 1994, the death rate from coronary heart disease decreased by 33% in the United States.

Like many drugs, statins don’t come without risks and have some serious side effects that people considering their use should be aware of, but approaching 30 years later, they remain among the most widely prescribed drugs in the world, with estimated annual sales of $14 billion. Atorvastatin (Lipitor), simvastatin (Zocor), rosuvastatin (Crestor), pravastatin (Pravachol), and lovastatin (Mevacor) are some examples. An X-ray crystal structure of the active site in the HMG-CoA reductase enzyme is shown in the accompanying graphic, along with a molecule of atorvastatin (purple) that is tightly bound in the active site and stops the enzyme from functioning. A good understanding of organic chemistry certainly paid off in this instance.

The X-ray crystal structure of the active site of the  H M G-coenzyme A reductase enzyme bound to atorvastatin (Lipitor) . The second figure shows the structure of Lipitor.
Order a print copy

As an Amazon Associate we earn from qualifying purchases.


This book may not be used in the training of large language models or otherwise be ingested into large language models or generative AI offerings without OpenStax's permission.

Want to cite, share, or modify this book? This book uses the Creative Commons Attribution-NonCommercial-ShareAlike License and you must attribute OpenStax.

Attribution information
  • If you are redistributing all or part of this book in a print format, then you must include on every physical page the following attribution:
    Access for free at
  • If you are redistributing all or part of this book in a digital format, then you must include on every digital page view the following attribution:
    Access for free at
Citation information

© Jan 9, 2024 OpenStax. Textbook content produced by OpenStax is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License . The OpenStax name, OpenStax logo, OpenStax book covers, OpenStax CNX name, and OpenStax CNX logo are not subject to the Creative Commons license and may not be reproduced without the prior and express written consent of Rice University.